Discontinuation of ropinirole and pramipexole in patients with Parkinson's disease: Clinical practice versus clinical trials

European Journal of Clinical Pharmacology

Volumn 64, Issue 10, 2008, Pages 1021-1026

  Arbouw, Maurits E L ^a,b,c   Movig, Kris L L ^c   Guchelaar, Henk Jan ^d   Poels, Petra J E ^e   Van Vugt, Jeroen P P ^c   Neef, Cees ^f   Egberts, Toine C G ^a,b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Discontinuation; Dopamine agonists; Parkinson's disease; Persistence; Pramipexole; Ropinirole

Indexed keywords

PRAMIPEXOLE; ROPINIROLE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT WITHDRAWAL;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; BENZOTHIAZOLES; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INDOLES; MALE; MIDDLE AGED; PARKINSON DISEASE; PATIENT COMPLIANCE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 53249095555     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0518-2     Document Type: Article

References (35)

1. O Rascol DJ Brooks AD Korczyn PP De Deyn CE Clarke AE Lang 2000 A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group N Engl J Med 342 1484 1491
2. RG Holloway I Shoulson S Fahn K Kieburtz A Lang K Marek 2004 Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial Arch Neurol 61 1044 1053
3. AL Whone RL Watts AJ Stoessl M Davis S Reske C Nahmias 2003 Slower progression of Parkinson's disease with ropinirole versus levodopa: the REAL-PET study Ann Neurol 54 93 101
4. The Parkinson Study Group 2002 Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression JAMA 287 1653 1661
5. JN Joyce MJ Millan 2007 Dopamine D3 receptor agonists for protection and repair in Parkinson's disease Curr Opin Pharmacol 7 100 105
6. HG Leufkens J Urquhart 1994 Variability in patterns of drug usage J Pharm Pharmacol 46 Suppl 1 433 437
7. DA van de Vijver RA Roos PA Jansen AJ Porsius A de Boer 2002 Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment Eur J Clin Pharmacol 58 157 161
8. C Marras A Kopp F Qiu AE Lang K Sykora KI Shulman 2007 Antipsychotic use in older adults with Parkinson's disease Mov Disord 22 319 323
9. LM Shulman A Minagar A Rabinstein WJ Weiner 2000 The use of dopamine agonists in very elderly patients with Parkinson's disease Mov Disord 15 664 668
10. NF Wieringa PA de Graeff GT van der Werf R Vos 1999 Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use Eur J Clin Pharmacol 55 537 544
11. NF Wieringa R Vos GT van der Werf WJ van der Veen PA de Graeff 2000 Co-morbidity of 'clinical trial' versus 'real-world' patients using cardiovascular drugs Pharmacoepidemiol Drug Saf 9 569 579
12. AC Egberts AW Lenderink FH de Koning HG Leufkens 1997 Channeling of three newly introduced antidepressants to patients not responding satisfactorily to previous treatment J Clin Psychopharmacol 17 149 155
13. KL Movig AC Egberts AW Lenderink HG Leufkens 2000 Selective prescribing of spasmolytics Ann Pharmacother 34 716 720
14. ME Arbouw JP van Vugt TC Egberts HJ Guchelaar 2007 Pharmacogenetics of antiparkinsonian drug treatment: a systematic review Pharmacogenomics 8 159 176
15. KA Grosset JL Reid DG Grosset 2005 Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease Mov Disord 20 1397 1404
16. BL Van Wijk OH Klungel ER Heerdink A de Boer 2006 Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation J Clin Epidemiol 59 11 17
17. O Rascol AJ Lees JM Senard Z Pirtosek JL Montastruc D Fuell 1996 Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease Clin Neuropharmacol 19 234 245
18. CH Adler KD Sethi RA Hauser TL Davis JP Hammerstad J Bertoni 1997 Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group Neurology 49 393 399
19. DJ Brooks RJ Abbott AJ Lees E Martignoni DV Philcox O Rascol 1998 A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease Clin Neuropharmacol 21 101 107
20. KD Sethi CF O'Brien JP Hammerstad CH Adler TL Davis RL Taylor 1998 Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group Arch Neurol 55 1211 1216
21. A Lieberman CW Olanow K Sethi P Swanson CH Waters S Fahn 1998 A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group Neurology 51 1057 1062
22. AD Korczyn ER Brunt JP Larsen Z Nagy WH Poewe S Ruggieri 1999 A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group Neurology 53 364 370
23. ER Brunt DJ Brooks AD Korczyn JL Montastruc F Stocchi 2002 A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa J Neural Transm 109 489 502
24. JH Im JH Ha IS Cho MC Lee 2003 Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study J Neurol 250 90 96
25. JP Hubble WC Koller NR Cutler JJ Sramek J Friedman C Goetz 1995 Pramipexole in patients with early Parkinson's disease Clin Neuropharmacol 18 338 347
26. A Lieberman A Ranhosky D Korts 1997 Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study Neurology 49 162 168
27. KM Shannon JP Bennett Jr JH Friedman 1997 Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group Neurology 49 724 728
28. M Guttman 1997 Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group Neurology 49 1060 1065
29. MM Pinter O Pogarell WH Oertel 1999 Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study J Neurol Neurosurg Psychiatry 66 436 441
30. The Parkinson Study Group 2000 Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial JAMA 284 1931 1938
31. O Pogarell T Gasser JJ van Hilten S Spieker S Pollentier D Meier 2002 Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study J Neurol Neurosurg Psychiatry 72 713 720
32. KS Wong CS Lu DE Shan CC Yang TH Tsoi V Mok 2003 Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease J Neurol Sci 216 81 87
33. P Navan LJ Findley JA Jeffs RK Pearce PG Bain 2003 Randomized, double-blind, 3-month parallel study of the effects of pramipexole, pergolide, and placebo on Parkinsonian tremor Mov Disord 18 1324 1331
34. Y Mizuno N Yanagisawa S Kuno M Yamamoto K Hasegawa H Origasa 2003 Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease Mov Disord 18 1149 1156
35. JC Moller WH Oertel J Koster G Pezzoli L Provinciali 2005 Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial Mov Disord 20 602 610